LIFECORE BIOMEDICAL, INC. \DE\ — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 62/100
What the filing says
Lifecore Biomedical and Alcon Research, LLC amended their contract manufacturing agreement effective November 1, 2026 (Amendment No. 3). Key changes: (1) contract term extended through December 31, 2034, with automatic 24-month renewals thereafter; (2) new exclusivity provision prohibits Lifecore from entering new agreements to develop, manufacture, or commercialize products competing with Alcon's current offerings from Nov 1, 2026 forward (existing competing arrangements grandfathered); (3) clarified remedies for non-conforming batches and updated minimum purchase obligations. Specific dollar amounts and percentage terms are redacted [***].
Why this rating
8-year term extension with Alcon—Lifecore's likely largest customer—provides revenue stability worth material fraction of $223M market cap. Exclusivity constraint is moderate risk, but grandfathering existing competing work limits impact. Redactions prevent full assessment.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.